Merck & Co., Inc. (MRK)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Robert M. Davis J.D. | Chairman, President & CEO | 5.57M | 8.44M | 1967 |
| Ms. Caroline Litchfield | Executive VP & CFO | 3.09M | -- | 1969 |
| Mr. Richard R. DeLuca Jr. | Executive VP & President of Merck Animal Health | 2.4M | 8.03M | 1963 |
| Mr. Sanat Chattopadhyay | Executive VP & President of Merck Manufacturing Division | 2.49M | 12.49M | 1960 |
| Dr. Dean Y. Li M.D., Ph.D. | Executive VP & President of Merck Research Laboratories | 3.61M | -- | 1963 |
| Mr. Dalton E. Smart III | Senior VP of Finance, Principal Accounting Officer & Global Controller | -- | -- | 1967 |
| Mr. David Michael Williams | Executive VP and Chief Information & Digital Officer | -- | -- | 1969 |
| Mr. Peter Dannenbaum | Vice President of Investor Relations | -- | -- | -- |
| Ms. Jennifer L. Zachary | Executive VP & General Counsel | 2.73M | 3.46M | 1978 |
| Lisa LeCointe-Cephas | Senior VP and Chief Ethics & Compliance Officer | -- | -- | 1982 |
Merck & Co., Inc.
- Sector:
- Healthcare
- Industry: Drug Manufacturers - General
- Full Time Employees:
- 70,000
Description
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians, wholesalers, government entities, veterinarians, distributors, animal producers, farmers, and pet owners. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
Corporate Governance
Recent Events
- Apr 11, 2024DEF 14A: Proxy StatementsSee Full Filing
- Apr 05, 2024Dividend Date
- Mar 19, 2024S-3ASR: Offering RegistrationsSee Full Filing
- Mar 14, 2024Ex-Dividend Date
- Mar 11, 2024SC 13D/A: Tender Offer/Acquisition ReportsSee Full Filing